An interventional study of WA-NG (NG-IMT) Telescope Prothesis in Age Related Macular Degeneration, sponsored by VisionCare, Inc.. Terminated at 2 sites in 2 countries. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2020-07-13.
Sponsored by VisionCare, Inc. · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies in Macular Degeneration by VisionCare, Inc. — 2 open to participants now, 3 under way, none of them phase 3. Macular Degeneration · VisionCare, Inc..
Among the 10 studies in Macular Degeneration by VisionCare, Inc., this one is the 7th largest by enrollment, is the only one that started in 2015, is one of 9 with no phase, and was the 6th registered.
1,461 studies on the registry are indexed under Macular Degeneration; 237 are open to participants now.
Browse Macular Degeneration studies →2 of the 10 studies in Macular Degeneration by VisionCare, Inc. are open now, in 4 countries. Recruiting first, the newest first:
VisionCare, Inc. · Sites in France, Germany, Italy
Ages 55+
VisionCare, Inc. · Sites in United States
Ages 65+
By country, each count listing its studies:
Of the 167 Macular Degeneration studies recruiting now, 118 (71%) set no upper age limit and 5 (3%) stop at 75 or younger; 19 take children under 18; 36 take healthy volunteers.
This study: 65 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 1 started in 2015.
This study's enrollment of 9 is below the median of 56 across 986 interventional studies indexed under Macular Degeneration.
Median enrollment 31 across the 10 interventional studies. Of the 3 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
VisionCare, Inc. is the lead sponsor of 11 studies on the registry; 3 are open to participants now.
2 of the studies in Macular Degeneration by VisionCare, Inc. that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07164378VisionCare, Inc.International Study of the SING IMT™ Prosthesis in Pseudophakic patiEnts With Stable Moderate to Profound Bilateral Central vIsion Impairment Due to adVancEd AMD / PERSPECTIVE Study | 2026-12-30 |
| NCT04796545VisionCare, Inc.Post-market Clinical Investigation of the SING IMT System, Model NG SI IMT 3X in Patients With End-stage Age-related Macular Degeneration | 2027-05 |
Add all 2 to your calendar (.ics) → With an account.
Among the 10 studies in Macular Degeneration by VisionCare, Inc., from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the safety of the updated Model WA-NG telescope prosthesis (hereafter WA-NG telescope), an injectable telescope device, in patients with bilateral moderate to profound central vision impairment due to end-stage age-related macular degeneration.
Patients will be screened for eligibility and informed consent will be obtained from those who meet screening criteria and are interested in participating in the study. Eligible patients will be examined preoperatively to obtain a medical history and to establish a baseline for ocular condition.
Postoperatively, patients will undergo ophthalmic evaluation at regular intervals as specified in this protocol.
**The following Inc. \& Exc. are sample and not completed list **
Main Exclusion Criteria:
Main Exclusion Criteria:
Implantable Miniature Telescope for end stage AMD (Age-related Macular Degeneration)
Device: WA-NG (NG-IMT) Telescope Prothesis
The WA-NG telescope prosthesis is the next generation telescopic implantable device which, when combined with the optics of the cornea, constitutes a telephoto system for improvement of visual acuity in patients with severe to profound vision impairment due to bilateral, end-stage age-related macular degeneration. The device is implanted in one of the patient's eyes. In this way, the implanted eye provides central vision and the non-implanted eye can continue to provide peripheral vision.
Positional stabilitytilt (the following parameter will be measured/ assessed :device centered (yes/ no) questionnaire)
Device positional stability will be assessed by slit lamp examination (microscope with a bright light used during an eye exam) and anterior segment Ocular Coherence Tomography (OCT is a non-invasive imaging test )
Time frame: 12 months
Positional stabilitytilt, the following parameter will be measured/ assessed : tilted (° C)
Device positional stability will be assessed by slit lamp examination (microscope with a bright light used during an eye exam) and anterior segment Ocular Coherence Tomography (OCT is a non-invasive imaging test )
Time frame: 12 months
Positional stabilitytilt , the following parameter will be measured/ assessed : malpositioned (yes/no) questionnaire
Device positional stability will be assessed by slit lamp examination (microscope with a bright light used during an eye exam) and anterior segment Ocular Coherence Tomography (OCT is a non-invasive imaging test )
Time frame: 12 months
Positional stabilitytilt , the following parameter will be measured/ assessed : endothelial cell count (Cells/mm2))
Time frame: 12 months
Positional stabilitytilt , the following parameter will be measured/ assessed : Intraocular pressure (mmHg)
Device positional stability will be assessed by slit lamp examination (microscope with a bright light used during an eye exam)
Time frame: 12 months
Number of Adverse events associated with the implant and use of the device will be evaluated.
Time frame: 12 months
Ran from May 2015 to primary completion in Jul 2020, 62 months.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Dec 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
VisionCare, Inc.